Does the media refer more to BBIO or TNGX?

In the previous week, BridgeBio Pharma had 4 more articles in the media than Tango Therapeutics. MarketBeat recorded 12 mentions for BridgeBio Pharma and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.71 beat BridgeBio Pharma's score of 0.43 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TNGX or ASND?

In the previous week, Tango Therapeutics had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 8 mentions for Tango Therapeutics and 5 mentions for Ascendis Pharma A/S. Tango Therapeutics' average media sentiment score of 0.71 beat Ascendis Pharma A/S's score of 0.48 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, TNGX or EXEL?

Exelixis has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tango Therapeutics $62.38M 62.32 -$101.59M -$0.83 N/A Exelixis $2.32B 5.68 $782.57M $3.18 16.49

Does the media favor TNGX or EXEL?

In the previous week, Exelixis had 34 more articles in the media than Tango Therapeutics. MarketBeat recorded 42 mentions for Exelixis and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.71 beat Exelixis' score of 0.24 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 10 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to TNGX or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 21 more articles in the media than Tango Therapeutics. MarketBeat recorded 29 mentions for Arrowhead Pharmaceuticals and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.71 beat Arrowhead Pharmaceuticals' score of 0.06 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to MDGL or TNGX?

In the previous week, Madrigal Pharmaceuticals and Madrigal Pharmaceuticals both had 8 articles in the media. Tango Therapeutics' average media sentiment score of 0.71 beat Madrigal Pharmaceuticals' score of 0.52 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tango Therapeutics (TNGX) Competitors

$26.88 -0.79 (-2.87%)

As of 11:02 AM Eastern

Compare

TNGX vs. BBIO, ASND, EXEL, ARWR, and MDGL

Should you buy Tango Therapeutics stock or one of its competitors? Tango Therapeutics's main competitors and comparable companies include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), Arrowhead Pharmaceuticals (ARWR), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tango Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Tango Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Tango Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.99	-$724.93M	-$3.74	N/A
Tango Therapeutics	$62.38M	62.32	-$101.59M	-$0.83	N/A

Tango Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Tango Therapeutics	N/A	-41.54%	-33.44%

BridgeBio Pharma currently has a consensus target price of $98.50, suggesting a potential upside of 16.26%. Tango Therapeutics has a consensus target price of $42.15, suggesting a potential upside of 56.84%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.82
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

BridgeBio Pharma has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 4 more articles in the media than Tango Therapeutics. MarketBeat recorded 12 mentions for BridgeBio Pharma and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.71 beat BridgeBio Pharma's score of 0.43 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BridgeBio Pharma and Tango Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Tango Therapeutics (NASDAQ:TNGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Tango Therapeutics had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 8 mentions for Tango Therapeutics and 5 mentions for Ascendis Pharma A/S. Tango Therapeutics' average media sentiment score of 0.71 beat Ascendis Pharma A/S's score of 0.48 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Tango Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tango Therapeutics currently has a consensus target price of $42.15, indicating a potential upside of 56.84%. Ascendis Pharma A/S has a consensus target price of $296.12, indicating a potential upside of 16.29%. Given Tango Therapeutics' higher probable upside, equities research analysts clearly believe Tango Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.06

Ascendis Pharma A/S has a net margin of 57.87% compared to Tango Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Tango Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Tango Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	62.32	-$101.59M	-$0.83	N/A
Ascendis Pharma A/S	$865.78M	18.35	-$258M	$8.67	29.37

Tango Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Tango Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Exelixis?

Tango Therapeutics (NASDAQ:TNGX) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

In the previous week, Exelixis had 34 more articles in the media than Tango Therapeutics. MarketBeat recorded 42 mentions for Exelixis and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.71 beat Exelixis' score of 0.24 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	10 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Exelixis has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	62.32	-$101.59M	-$0.83	N/A
Exelixis	$2.32B	5.68	$782.57M	$3.18	16.49

Tango Therapeutics presently has a consensus target price of $42.15, suggesting a potential upside of 56.84%. Exelixis has a consensus target price of $49.79, suggesting a potential downside of 5.04%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Exelixis	2 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.26

Exelixis has a net margin of 35.33% compared to Tango Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Exelixis	35.33%	42.17%	31.76%

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Summary

Exelixis beats Tango Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Tango Therapeutics (NASDAQ:TNGX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tango Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Tango Therapeutics' return on equity of -41.54% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Arrowhead Pharmaceuticals has higher revenue and earnings than Tango Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	62.32	-$101.59M	-$0.83	N/A
Arrowhead Pharmaceuticals	$829.45M	15.21	-$1.63M	-$2.25	N/A

In the previous week, Arrowhead Pharmaceuticals had 21 more articles in the media than Tango Therapeutics. MarketBeat recorded 29 mentions for Arrowhead Pharmaceuticals and 8 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.71 beat Arrowhead Pharmaceuticals' score of 0.06 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Tango Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Tango Therapeutics currently has a consensus target price of $42.15, indicating a potential upside of 56.84%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, indicating a potential upside of 8.67%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Summary

Tango Therapeutics beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Tango Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.82	-$288.28M	-$12.89	N/A
Tango Therapeutics	$62.38M	62.32	-$101.59M	-$0.83	N/A

In the previous week, Madrigal Pharmaceuticals and Madrigal Pharmaceuticals both had 8 articles in the media. Tango Therapeutics' average media sentiment score of 0.71 beat Madrigal Pharmaceuticals' score of 0.52 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its stock price is 201% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tango Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Tango Therapeutics' return on equity of -41.54% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Tango Therapeutics	N/A	-41.54%	-33.44%

Madrigal Pharmaceuticals presently has a consensus price target of $689.93, suggesting a potential upside of 29.70%. Tango Therapeutics has a consensus price target of $42.15, suggesting a potential upside of 56.84%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Tango Therapeutics beats Madrigal Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNGX vs. The Competition

Export

Metric	Tango Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.89B	$3.73B	$7.05B	$12.94B
Dividend Yield	N/A	3.77%	2.58%	10.06%
P/E Ratio	-32.37	9.12	268.69	24.87
Price / Sales	62.32	1,263.91	586.52	95.58
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	10.46	17.80	11.29	6.44
Net Income	-$101.59M	-$13.25M	$3.44B	$347.05M
7 Day Performance	-8.46%	3.60%	2.23%	1.00%
1 Month Performance	-13.47%	-1.25%	-0.21%	-0.59%
1 Year Performance	319.30%	62.01%	75.56%	22.26%

Tango Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNGX Tango Therapeutics	2.4959 of 5 stars	$26.88 -2.9%	$42.15 +56.8%	+318.6%	$3.89B	$62.38M	N/A	90	Earnings Report
BBIO BridgeBio Pharma	2.7814 of 5 stars	$82.07 +2.6%	$95.21 +16.0%	+81.8%	$16.03B	$502.08M	N/A	400	News Coverage Earnings Report
ASND Ascendis Pharma A/S	4.5529 of 5 stars	$245.21 +0.7%	$296.72 +21.0%	+33.5%	$15.33B	$814.57M	28.34	1,189	Upcoming Earnings
EXEL Exelixis	2.2297 of 5 stars	$56.01 +1.7%	$49.50 -11.6%	+40.4%	$14.09B	$2.32B	18.62	1,077	Positive News Earnings Report Analyst Downgrade
ARWR Arrowhead Pharmaceuticals	1.7798 of 5 stars	$89.32 +3.9%	$96.92 +8.5%	+437.9%	$12.59B	$622.01M	N/A	400	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNGX) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tango Therapeutics (TNGX) Competitors

TNGX vs. BBIO, ASND, EXEL, ARWR, and MDGL

How does Tango Therapeutics compare to BridgeBio Pharma?

Summary

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Tango Therapeutics compare to Exelixis?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Tango Therapeutics compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tango Therapeutics (TNGX) Competitors

TNGX vs. BBIO, ASND, EXEL, ARWR, and MDGL

How does Tango Therapeutics compare to BridgeBio Pharma?

Which has better earnings & valuation, BBIO or TNGX?

Is BBIO or TNGX more profitable?

Do analysts rate BBIO or TNGX?

Which has more risk and volatility, BBIO or TNGX?

Do institutionals and insiders have more ownership in BBIO or TNGX?

Does the media refer more to BBIO or TNGX?

Summary

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Does the media refer more to TNGX or ASND?

Do institutionals and insiders believe in TNGX or ASND?

Do analysts rate TNGX or ASND?

Is TNGX or ASND more profitable?

Which has stronger valuation & earnings, TNGX or ASND?

Which has more volatility & risk, TNGX or ASND?

Summary

How does Tango Therapeutics compare to Exelixis?

Does the media favor TNGX or EXEL?

Which has preferable valuation and earnings, TNGX or EXEL?

Do analysts prefer TNGX or EXEL?

Is TNGX or EXEL more profitable?

Do institutionals & insiders hold more shares of TNGX or EXEL?

Which has more volatility & risk, TNGX or EXEL?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Do institutionals and insiders believe in TNGX or ARWR?

Is TNGX or ARWR more profitable?

Which has stronger earnings and valuation, TNGX or ARWR?

Does the media refer more to TNGX or ARWR?

Which has more risk & volatility, TNGX or ARWR?

Do analysts recommend TNGX or ARWR?

Summary

How does Tango Therapeutics compare to Madrigal Pharmaceuticals?

Which has stronger valuation & earnings, MDGL or TNGX?

Does the media refer more to MDGL or TNGX?

Which has more risk & volatility, MDGL or TNGX?

Do institutionals & insiders hold more shares of MDGL or TNGX?

Is MDGL or TNGX more profitable?

Do analysts rate MDGL or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools